{
  "abstract": "Objective A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, has been associated with lack of response to first-line therapy in the Care in early RA trial. This study aimed to determine the association of this antibody panel with first-line therapy response in an independent cohort.Methods Anti-UH-RA.305/318/329 antibody reactivity was determined using ELISA in 165 baseline samples of the CAP48 cohort, an observational cohort of patients with early and naïve RA treated mainly with methotrexate monotherapy. Multivariable analyses assessed associations between baseline antibody reactivity and failure to reach remission or low disease activity (LDA) at 3, 6, 9 and 24 months according to the Disease Activity Score 28-joint C-reactive protein (DAS28CRP) and clinical/simplified disease activity index (SDAI).Results In the total RA cohort, baseline anti-UH-RA.305/318/329 antibody reactivity was significantly higher in patients not achieving LDA versus those achieving LDA at 9 months (31.6% vs 11.3% for DAS28CRP/SDAI; OR 3.64, 95% CI 1.34 to 9.91, p=0.045). In patients with seronegative RA, a significant association between antibody reactivity and not achieving LDA based on DAS28CRP (42.1% vs 12.5%; OR 5.09, 95% CI 1.2 to 27.0, p=0.05) was already observed at 6 months. After 24 months, baseline antibody positivity remained significantly associated with not achieving LDA based on SDAI (OR 29.9, 95% CI 2.5 to 109.2, p=0.01) in patients with seronegative status.Discussion In the CAP48 cohort, the anti-UH-RA antibody panel was associated with a lack of response to first-line therapy for certain clinical measures, observed at 9 months in the total RA cohort and at 6 and 24 months in patients with seronegative status. The antibody panel should be further validated for its use in early personalised RA treatment.",
  "authors": [
    {
      "affiliations": [
        "Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium"
      ],
      "name": "Sukayna Fadlallah"
    },
    {
      "affiliations": [
        "Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium"
      ],
      "name": "Judith Fraussen"
    },
    {
      "affiliations": [
        "Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium"
      ],
      "name": "Pieter Ruytinx"
    },
    {
      "affiliations": [
        "Cliniques Universitaires Saint-Luc - Université catholique de Louvain (UCLouvain), Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium"
      ],
      "name": "Tatiana Sokolova"
    },
    {
      "affiliations": [
        "Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium",
        "Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KULeuven, Leuven, Belgium"
      ],
      "name": "Patrick Verschueren"
    },
    {
      "affiliations": [
        "Cliniques Universitaires Saint-Luc - Université catholique de Louvain (UCLouvain), Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium"
      ],
      "name": "Patrick Durez"
    },
    {
      "affiliations": [
        "Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium"
      ],
      "name": "Veerle Somers"
    }
  ],
  "title": "Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort",
  "uid": "52c5b8a5-15aa-5de4-8c67-e00ccbe757c9"
}